Companies: 10,795·Total market cap: $144.5T
Akari Therapeutics, Plc

Akari Therapeutics, Plc

AKTXNASDAQHealthcare● Active
$15.45
+$0.38(+2.49%)
Market Cap$17678146
P/E Ratio—
52W High$54
52W Low$3.015
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Akari Therapeutics, Plc (AKTX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · AKTX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1448.00aktx eps ttm · aktx earnings per shareEarnings history
PE Ratio (TTM)—aktx pe ratio ttm · aktx price to earningsPE Ratio deep dive
Revenue (TTM)0.00aktx revenue ttm · aktx annual revenueFull revenue history
Dividend YieldNo Dividenddoes aktx pay dividends · aktx dividend yieldDividend history
Shares Outstanding21,040aktx shares outstanding · aktx floatShares outstanding history
Next EarningsAug 18, 2026Est.aktx earnings date · aktx next earningsEarnings history

Explore Akari Therapeutics, Plc Data

aktx stock data · financials
Market Cap$17.4Maktx market cap · aktx valuation
Analyst Forecast$1200 · Buy
DividendsNo Dividenddoes akari therapeutics, plc pay dividends · aktx dividend yield
Revenue—akari therapeutics, plc annual revenue · aktx revenue
EarningsEPS $-20800.00+84.34%aktx earnings · aktx eps
PE Ratio—aktx pe ratio · aktx price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
akari therapeutics, plc revenue · aktx revenue 2025
FY 2025Net Income-$17.3M▲ +12.60% YoY
202320242025
akari therapeutics, plc net income · aktx profit 2025
FY 2025EPS$-20800.00▲ +84.34% YoY
202320242025
aktx eps · akari therapeutics, plc earnings per share 2025
TTM:Revenue: $0.00Net Income: -$28.0MEPS: $-1448.00View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy8 analystsis aktx a buy · aktx analyst rating
Strong Buy
0
Buy
6
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$1200.00Low
$15.45Current
$1200.00Avg Target7669.50% upside
$1200.00High
aktx price target · aktx 12 month forecast

Total: 8 · Buy rate: 75.0%

The AKTX analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $1200.00, representing +7669.50% upside from the current price of $15.45.

Stock Performance

Full History
1D+0.86%
1W+7.12%
1M+143.20%
3M+51.24%
YTD+31.49%
1Y-69.60%
5Y-98.94%

About Akari Therapeutics, Plc

CEOAbizer Gaslightwala
IPO DateJan 6, 2014
Employees8
CountryGB
Websiteakaritx.com

Akari Therapeutics, Plc a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a secon…

BiotechnologyHealthcareNASDAQADRGB

what is akari therapeutics, plc · aktx stock overview · akari therapeutics, plc company profile · who is akari therapeutics, plc ceo · aktx NASDAQ · akari therapeutics, plc headquarters · akari therapeutics, plc business segments

About Stock Overview & Key Data

Akari Therapeutics, Plc (AKTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 6, 2014. As of the latest trading session, AKTX stock price is $15.45, with a market capitalization of $17.4M. The stock has returned -69.60% over the past 12 months and +31.49% year-to-date.

According to 8 Wall Street analysts, the consensus rating for Akari Therapeutics, Plc stock is Buy, with an average 12-month price target of $1200.00. In fiscal year 2025, Akari Therapeutics, Plc reported revenue of — and net income of -$17.3M. For detailed data — including Akari Therapeutics, Plc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Akari Therapeutics, Plc (AKTX) stock price is $15.45. The stock is traded on NASDAQ under the ticker symbol AKTX. The 52-week range is $3.02 – $54.00.

AKTX stock priceAKTX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice